longboardpharma.com (LBPH) - Forward P/S Multiple
Longboard Pharmaceuticals complies with environmental regulations through laboratory safety and digital documentation. The organization's forward P/S, with a value fixed at , links market value to fundamentals. Longboard Pharmaceuticals possesses protected patents and liquid capital. The business's financial success relies on the commercial launch of innovative treatments for developmental delays and epilepsy.
Comprehensive metric breakdowns and analytics for Longboard (LBPH)
- market price and analyst price targets:
- market capitalization indicators:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Longboard Pharmaceuticals|LBPH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Longboard Pharmaceuticals|LBPH - Company Aggregate Debts|Debt to Book Capitalization Ratio Longboard|LBPH - Company Long-Term Loans and Borrowings|Company Short-Term Debt Longboard Pharmaceuticals|Quick Ratio longboardpharma.com
- net income and valuation multiples indicators:
LBPH - Net Profit|Projected Future Earnings Longboard Pharmaceuticals|LBPH - Price to Earnings Ratio|Forward P/E Multiple Longboard Pharma|LBPH - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Longboard|LBPH - Operating profit EBITDA|Net earnings per share for the last 12 months Longboard Pharmaceuticals|LBPH - Earnings per share for the last four quarters|Quarterly EPS earnings growth longboardpharma.com|LBPH - Expected net earnings per share growth this year|Earnings growth forecast for next year Longboard Pharmaceuticals
- company sales and revenue statistics:
Fundamental company analysis:LBPH (Longboard Pharmaceuticals, Inc.)
For Longboard Pharmaceuticals (LBPH), whose neurology operations are shielded from geopolitical risks by the US market, this indicator serves as a gauge of market optimism regarding future sales. By analyzing the forward price-to-sales ratio chart, an investor assesses the relationship between current market capitalization and projected revenue, where elevated values signal that the asset is overbought, while low values indicate an undervaluation of growth potential.
Key competitors
Price-to-Projected Revenue Ratio Biogen BIIB|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|AXSM (Axsome Corp) - Market Cap to Projected Revenue|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|xenon-pharma.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Therapeutics, Inc.|Supernus Pharmaceuticals, Inc. - Future Price to Revenue|Forward P/S Multiple CPRX|DNLI (Denali Corp) - Forward Price to Sales|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward P/S Multiple biohavenpharma.com BHVN|AMLX - Price-to-Projected Revenue Ratio|Forward Price to Sales TRVI (Trevi Therapeutics Inc)|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Prothena Corporation|Forward P/S Multiple ALEC|Forward Price-to-Revenue Multiple Annexon Biosciences ANNX|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR - Forward P/S Multiple|NMRA (Neumora Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|SCLX: Price to Expected Revenue Ratio|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CGTX|Forward Price-to-Revenue Multiple inhibikase.com IKT|Forward P/S Multiple SAVA (Cassava Sciences)|Forward P/S Multiple Assertio Holdings ASRT|COYA - Price-to-Projected Revenue Ratio|VTGN: Price-to-Projected Revenue Ratio|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|ABOS - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CervoMed|Price-to-Projected Revenue Ratio ATHE|Forward P/S Multiple CLNN|Price-to-Projected Revenue Ratio PEPG (pepgen.com)|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|RLMD (relmada.com) - Future Price to Revenue|Annovis Bio - Forward P/S Multiple|Forward Price to Sales GRCE (Grace Therapeutics, Inc.)|Firefly Neuroscience Inc (AIFF) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue KLTO|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revivapharma.com RVPH|Forward Price-to-Revenue Multiple MTVA (MetaVia Inc)|Forward P/S Multiple NeurAxis Inc. (NRXS)|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|Forward Price to Sales PASG|NEUP - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio minervaneurosciences.com|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|ADXN (Addex Therapeutics Ltd.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Alzamend Neuro Inc.|Market Cap to Future Revenue Ratio Cyclerion CYCN|Price-to-Projected Revenue Ratio Protagenic Therapeutics (PTIX)|pasitheaclinics.com - Market Cap to Projected Revenue|Forward P/S Multiple CRGT (Cortigent)|Projected Price to Revenue Avenue Therapeutics Inc.|Brainstorm Cell Therapeutics, Inc. - Forward P/S Multiple|CARA: Price-to-Projected Revenue Ratio|Chromocell Therapeutics (CHRO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Eliem Therapeutics Inc. (ELYM)|ITCI (Intra-Cellular Therapies Inc.) - Forward P/S Multiple|Forward P/S Multiple Marinus Pharmaceuticals Inc|Price-to-Projected Revenue Ratio NKGen (NKGN)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|SNPX: Market Cap to Projected Revenue|TRVN: Forward Price-to-Revenue Multiple|Forward Price to Sales VIGL (Vigil Neuroscience)|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CERE (Cerevel Corp)
